29th November 2016
The anticipated arrival of the pregnancy termination pill Mifegymiso in Canada has been delayed until the New Year. As per the drug’s pharmaceutical company Celopharma Inc, Mifepgymiso will be launched somewhere in January. The Company president, Paula Tenenbaum gave little information, but revealed that there will be delay in the introduction of the new abortion pill in Canada in regards to some change in the manufacturing site. Last month, however the company president, Tenenbaum had commented that Mifegymiso will be approved and will debut in the Canadian market in November.
Health Canada restricts access to Mifegymiso
The provincial government body had faced some opposition for placing too many controversial restrictions which included the medication’s need to be dispensed by a doctor to patients. The critics feared that such restrictions would restrict the access for patients in the rural area and remote areas. Due to such restriction many women choose to buy abortion pill online.
Restrictions on Mifegymiso
The pill is also limited to be used within seven weeks of gestational period, whereas the norm is within 10 – 12 weeks (which have been proven to be effective). It also won’t be covered by the provincial drug plans; therefore it must be paid for through the woman’s own pocket. The cost of Mifegymiso is also quite steep, which has a $300 price tag.
The drug has been available for more than two and half decades and is approved in more than sixty countries with variations in restrictions.
Clopharma president hopes for a quick response
The president of the pharmaceutical company, Tenenbaum had said that the company was working in order to have the submission revised to the Health Canada that would increase the recommended usage to up to nine weeks of gestational period ( i.e. nine weeks after the woman’s last menstrual cycle). She also expressed her preference to have the pharmacist directly dispense the medication to the patients. Tennenbaum also commented on Monday the 28th , that she hoped to get a quick response from Health Canada, preferable somewhere in December.
A spokesperson from Health Canada, explained that the federal agency does not disclose details regarding the status of the drug approval applications, even so they firmly support the rights of women to make her choice regarding her reproductively. The department is committed to curtail any unwarranted delays in the review of any submission. All the drug approval decisions made by the provincial healthcare body are based on the detailed scientific review and therefore it continues to work with Celopharma on its application.
What is Mifegymiso?
Mifegymiso is a combination of two drugs, i.e. Mifepristone and Misoprostol. One is a progesterone blocking drug while the other is a prostaglandin analogue. The combination of Mifepgymiso is taken on two separate days.
First Mifepristine is taken to block the progesterone hormone which blocks the hormones that help continue the pregnancy. While the other medicine Misoprostol helps in inducing contractions in the womb and eject the conception tissues from the body through vaginal discharge. The success rates of combination of these pills have been 96%-97% since it was introduced.
Doris R Looney
Email Id - DorisRLooney020@gmail.com
Dallas, TX, 214
phone no – 1-202-555-0152